Last reviewed · How we verify
COVAX only (1st and 2nd dose)
COVAX is an inactivated COVID-19 vaccine that stimulates the immune system to produce antibodies and cellular immunity against SARS-CoV-2 by presenting inactivated viral particles.
COVAX is an inactivated COVID-19 vaccine that stimulates the immune system to produce antibodies and cellular immunity against SARS-CoV-2 by presenting inactivated viral particles. Used for COVID-19 prevention (SARS-CoV-2 infection).
At a glance
| Generic name | COVAX only (1st and 2nd dose) |
|---|---|
| Sponsor | China National Biotec Group Company Limited |
| Drug class | Inactivated viral vaccine |
| Target | SARS-CoV-2 spike protein and other viral antigens |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) SARS-CoV-2 virus particles that cannot cause infection but trigger both humoral (antibody) and cell-mediated immune responses. The two-dose regimen allows for priming and boosting of the adaptive immune response to provide protection against COVID-19 infection and severe disease.
Approved indications
- COVID-19 prevention (SARS-CoV-2 infection)
Common side effects
- Injection site pain or swelling
- Fever
- Fatigue
- Headache
- Myalgia
Key clinical trials
- Evaluation of Immunogenicity and Safety of Combined Immunization of COVID-19 Vaccine (Produced in Beijing) and PPV23 / IIV4 (PHASE4)
- Evaluation of Immunogenicity and Safety of Combined Immunization of COVAX (Produced in Wuhan) and PPV23 / IIV4 (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: